skip to main content

Biosimilars — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateDermatopharmacologyBiosimilarsSCE Dermatology

A 50-year-old man with widespread psoriasis has been stable on Adalimumab for 3 years. His dermatologist discusses switching to an Adalimumab biosimilar for cost reasons. What is the key regulatory principle regarding biosimilars?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Biosimilars are highly similar to the originator with no clinically meaningful differences in quality, safety, or efficacy

Biosimilars are biological medicines that are highly similar to an already approved reference (originator) biological medicine, with no clinically meaningful differences in terms of quality, safety, or efficacy. The EMA/MHRA approval process requires extensive comparability studies (structural, functional, and clinical). NHS England and BAD support switching from originator to biosimilar biologics in stable patients, which has been shown to be safe and effective in large registries (e.g., NOR-SWITCH trial). Cost savings from biosimilar adoption are substantial. Patients should be informed about the switch and monitored for any change in response or adverse events.

Reference: BAD 2020 Biologic Guidelines; MHRA Biosimilar Guidance; NHS England